// App-Quantinova.ai

6013 : Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.

Researchers

Presenter

  • Jonas A. De Souza

Principal Investigators

  • Theodore Karrison

  • Bernadette Libao

  • Francis P. Worden

  • Monika Krzyzanowska

  • David N. Hayes

  • Eric Winquist

  • Vassiliki Saloura

  • Victoria Meucci Villaflor

  • Tanguy Y. Seiwert

  • Walter Michael Stadler

  • Ezra E.W. Cohen

  • Rebecca B. Schechter

  • Everett E. Vokes

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Cancer Care Ontario, Toronto, ON, Canada

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • London Health Sciences Center, London, ON, Canada

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

  • University of California, San Diego, La Jolla, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Thyroid Cancer

Biomarkers

  • Disseminated tumor cells

  • Vascular endothelial growth factor A

Drug/Treatment

  • Lenalidomide

  • Cediranib

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01208051

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved